Find clinical trials for Pancreatic Cancer in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Rochester, MN, USA:
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate...
Rochester, Minnesota, United States and 15 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Rochester, Minnesota, United States and 15 other locations
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Rochester, Minnesota, United States and 32 other locations
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorect ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 7 other locations
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Phase 3
Rochester, Minnesota, United States and 57 other locations
The goal of this study is to test A2B694, an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorec ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 10 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Rochester, Minnesota, United States and 65 other locations
to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...
Phase 2
Rochester, Minnesota, United States and 63 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Rochester, Minnesota, United States and 23 other locations
as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors...
Phase 1
Rochester, Minnesota, United States and 15 other locations
Clinical trials
Research sites
Resources
Legal